HHS awards $24.9M for Structural Genomics Centers for Infectious Diseases to Seattle Biomedical Research Institute

Contract Overview

Contract Amount: $24,932,522 ($24.9M)

Contractor: Seattle Biomedical Research Institute

Awarding Agency: Department of Health and Human Services

Start Date: 2012-08-31

End Date: 2017-08-31

Contract Duration: 1,826 days

Daily Burn Rate: $13.7K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 4

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: IGF::OT::IGF OTHER FUNCTIONS - STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES

Place of Performance

Location: SEATTLE, KING County, WASHINGTON, 98109

State: Washington Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $24.9 million to SEATTLE BIOMEDICAL RESEARCH INSTITUTE for work described as: IGF::OT::IGF OTHER FUNCTIONS - STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES Key points: 1. The contract awarded to Seattle Biomedical Research Institute is for research and development in biotechnology. 2. The contract was awarded under full and open competition. 3. The contract duration is 5 years, with a total value of $24.9 million. 4. The primary sector for this spending is Research and Development.

Value Assessment

Rating: good

The contract type is Cost Plus Fixed Fee, which allows for cost reimbursement plus a fixed fee. This is common for R&D contracts where costs can be uncertain. The total award of $24.9M over 5 years suggests a moderate annual spend.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. This method generally promotes competitive pricing and ensures the government receives the best value.

Taxpayer Impact: The competitive nature of the award suggests that taxpayer funds are being used efficiently to secure specialized research services.

Public Impact

Funding supports critical research into infectious diseases, potentially leading to new treatments or preventative measures. The award to a specific research institute contributes to the advancement of biotechnology and public health. Long-term contracts like this provide stability for research institutions to pursue complex scientific goals.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This contract falls within the Biotechnology Research and Development sector, a critical area for public health. Spending benchmarks for similar R&D contracts can vary widely based on scope and duration, but this award appears to be of moderate size for a multi-year research initiative.

Small Business Impact

The data does not indicate whether small businesses were involved as subcontractors. The primary awardee, Seattle Biomedical Research Institute, is a research institution, not typically classified as a small business.

Oversight & Accountability

The contract is managed by the National Institutes of Health (NIH), a part of HHS, which has established oversight mechanisms for research grants and contracts to ensure accountability and proper use of funds.

Related Government Programs

Risk Flags

Tags

research-and-development-in-biotechnolog, department-of-health-and-human-services, wa, definitive-contract, 10m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $24.9 million to SEATTLE BIOMEDICAL RESEARCH INSTITUTE. IGF::OT::IGF OTHER FUNCTIONS - STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES

Who is the contractor on this award?

The obligated recipient is SEATTLE BIOMEDICAL RESEARCH INSTITUTE.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $24.9 million.

What is the period of performance?

Start: 2012-08-31. End: 2017-08-31.

What is the specific scientific output expected from these Structural Genomics Centers for Infectious Diseases?

The expected scientific output would likely involve the detailed structural analysis of proteins and other biomolecules relevant to infectious diseases. This could include identifying potential drug targets, understanding disease mechanisms at a molecular level, and providing foundational data for the development of new diagnostics, vaccines, and therapeutics. The centers aim to accelerate the pace of discovery in infectious disease research.

What are the primary risks associated with a Cost Plus Fixed Fee contract for R&D?

The primary risks with a Cost Plus Fixed Fee (CPFF) contract in R&D include potential cost overruns if the contractor's actual costs exceed initial estimates, even though the fee is fixed. There's also a risk that the contractor might not be sufficiently incentivized to control costs, as they are reimbursed for expenses. Effective oversight and clear performance metrics are crucial to mitigate these risks.

How does this funding contribute to the overall effectiveness of infectious disease research in the US?

This funding contributes to the overall effectiveness by providing dedicated resources for fundamental structural biology research directly applicable to infectious diseases. By supporting specialized centers, it fosters collaboration and expertise, potentially accelerating breakthroughs that might not occur with fragmented or short-term funding. This investment strengthens the nation's capacity to combat existing and emerging infectious disease threats.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in Biotechnology

Product/Service Code: RESEARCH AND DEVELOPMENTN – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Offers Received: 4

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 307 WESTLAKE AVE N STE 500, SEATTLE, WA, 98109

Business Categories: Category Business, Corporate Entity Tax Exempt, Nonprofit Organization, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $24,932,522

Exercised Options: $24,932,522

Current Obligation: $24,932,522

Subaward Activity

Number of Subawards: 23

Total Subaward Amount: $15,597,232

Contract Characteristics

Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline

Start Date: 2012-08-31

Current End Date: 2017-08-31

Potential End Date: 2017-08-31 00:00:00

Last Modified: 2018-06-12

More Contracts from Seattle Biomedical Research Institute

View all Seattle Biomedical Research Institute federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending